Article
Emerging therapies for haemophilia ‐ Global perspective
1 May 2018
Abstract excerpt
The therapeutic options for people with haemophilia (PWH) have rapidly evolved in the last 5 years. Moving on from conventional plasma-derived and recombinant clotting factor concentrates (CFC), there now are extended half-life CFCs (~1.8× for FVIII and ~4.5× for FIX) to as well as several novel haemostasis agents administered subcutaneously (weekly to monthly) such as bispecific antibody which brings together...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
